Several preclinical studies confirmed that dual pharmacological inhibition of PI3K and MAPK pathways (via both continuous and intermittent dosing) improved therapeutic activity in basal-like breast cancer and melanoma models, as well as cell lines with mutations in both pathways [29,30,31]. The gene discussed is PIK3CA; the disease is melanoma.